(Reuters) - Investors pulled heavily out of global equity funds during the week through March 19 on lingering worries over the potential impact of U.S. President Donald Trump's aggressive trade policies on global economy.
The three cryptocurrencies at the top of my shopping list are Bitcoin (CRYPTO: BTC), Solana (CRYPTO: SOL) and Ondo (CRYPTO: ONDO). From my perspective, Solana remains the one Layer 1 blockchain network capable of toppling Ethereum from its top perch.
The rally in European stock markets took a breather as EU leaders struggled to secure a €5 billion funding package for Ukraine. Investor sentiment was further dampened by the ECB’s cautious outlook on the economy and inflation, triggering selloffs, particularly in the defence and automotive sectors.View on euronews
(Reuters) -FedEx's shares fell 11% on Friday after the parcel delivery firm cut its annual forecasts, fanning worries about the health of U.S. manufacturing amid uncertainty from the Trump administration's sweeping tariffs on trading partners. CEO Raj Subramaniam warned a day earlier that the company was navigating a very "challenging operating environment" and "weakness in the industrial economy" was weighing on its higher-margin business-to-business volumes. The company's shares hit their lowest in nearly two years on Friday.
Everyone wants an edge when it comes to investing in highly volatile assets like XRP (CRYPTO: XRP), Solana (CRYPTO: SOL), Ethereum (CRYPTO: ETH) and other cryptocurrencies. If you're like most people who hold cryptocurrencies, you probably broadly understand that such assets live on blockchains, which in theory can give them certain properties that dollars in your bank account can't have, like being linked to something such as ownership of a non-fungible token (NFT). Thus, the one thing that can dramatically improve your investment research process in crypto (and therefore your returns) is to get your hands dirty by working with the actual technology underpinning your coins rather than simply pressing "buy" or "sell" and then letting them sit quietly in your portfolio.
What a brutal six months it’s been for JELD-WEN. The stock has dropped 61.7% and now trades at $6.11, rattling many shareholders. This might have investors contemplating their next move.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX) and the rest of the branded pharmaceuticals stocks fared in Q4.